A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists

Journal of Medicinal Chemistry

Volumn 52, Issue 17, 2009, Pages 5330-5343

  McKinnell, R Murray ^a   Armstrong, Scott R ^a   Beattie, David T ^a   Choi, Seok Ki ^a   Fatheree, Paul R ^a   Gendron, Roland A L ^a   Goldblum, Adam ^a   Humphrey, Patrick P ^a   Long, Daniel D ^a   Marquess, Daniel G ^a   Shaw, J P ^a   Smith, Jacqueline A M ^a   Turner, S Derek ^a   Vickery, Ross G ^a  

^a THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ISOPROPYL 2 OXO 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID [8 [2 HYDROXY 3 (4 METHANESULFONYLPIPERAZIN 1 YL)PROPYL] 8 AZABICYCLO[3.2.1]OCT 3 YL]AMIDE; POTASSIUM CHANNEL HERG; SEROTONIN 4 AGONIST; TEGASEROD; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; GASTROINTESTINAL MOTILITY DISORDER; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; IRRITABLE COLON; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; MYENTERIC PLEXUS; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BINDING SITES; BIOLOGICAL AVAILABILITY; CELL LINE; DOGS; DRUG DESIGN; GASTROINTESTINAL DISEASES; HUMANS; MALE; MOVEMENT; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN, 5-HT4; SUBSTRATE SPECIFICITY;

EID: 69949089934     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900881j     Document Type: Article

References (47)

1. Saxena, P. R. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol. Ther. 1995, 339-368.
2. Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 1994, 157-203. (Pubitemid 24185150)
3. Dumuis, A.; Bouhelal, R.; Sebben, M.; Cory, R.; Bockaert, J. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol. Pharmacol. 1988, 34, 880-887.
4. 4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br. J. Pharmacol. 1995, 114, 993-998.
5. Hegde, S. S.; Eglen, R. M. Peripheral 5-HT4 receptors . FASEB J. 1996, 10, 1398-1407.
6. 4 receptors by GR 113808. Br. J. Pharmacol. 1993, 110, 1172-1174.
7. Lefebvre, H.; Contesse, V.; Delarue, C.; Vaudry, H.; Kuhn, J. M. Serotonergic regulation of adrenocortical function. Hormone Metab. Res. 1998, 30, 398-403.
8. 4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazolone and substituted benzamide agonists and antagonists. Br. J. Pharmacol. 1996, 118, 1965-1970.
9. (a) Sanger, G. J. 5-Hydroxytryptamine and functional bowel disorders. Neurogastroenterol. Motil. 1996, 8, 319-331.
10. (b) Tonini, M.; Fabio, P. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis. 2006, 24, 59-69.
11. 4 agonist, prucalopride, in healthy humans. Gut 1999, 44, 682-686.
12. Maillet, M.; Robert, S. J.; Lezoualc'h, F. New Insights into Serotonin 5-HT4 Receptors: A Novel Therapeutic Target for Alzheimer's Disease? Curr. Alzheimer Res. 2004, 1, 79-85.
13. 4 receptors mediate arrhythmias? Trends Pharmacol. Sci. 1994, 15, 451-455.
14. 4 receptor in guinea pig ileum and rat oesophagus: role in peristaltis. In Serotonin: Molecular Biology, Receptors and Functional Effects; Fozard, J. R., Saxena, P. R., Eds.; Birkhâuser Verlag: Basel, Switzerland, 1991; pp 232-242.
15. 3 receptors. J. Pharmacol. Exp. Ther. 1999, 288, 93-97.
16. Briejer, M. R.; Bosmans, J. P.; Van Daele, P.; Jurzak, M.; Heylen, L.; Leysen, J. E.; Prins, N. H.; Schuurkes, J. A. J. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur. J. Pharmacol. 2001, 423, 71-83.
17. 4 receptor types in isolated human colon smooth muscle. Br. J. Pharmacol. 1994, 112 (Proc. Suppl. May), 102P.
18. Hansen, M. B.; Skadhauge, E. Signal transduction pathways for serotonin as an intestinal secretagogue. Comp. Biochem. Physiol. 1997, 118, 283-290.
19. Scarpignato, C.; Pelosini, I. Management of the irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Can. J. Gastroenterol. 1999, 13, 50A-65A.
20. Rampe, D.; Roy, M.-L.; Dennis, A.; Brown, A. M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 1997, 417, 28-32.
21. Sloots, C. E. J.; Poen, A. C.; Kerstens, R.; Stevens, M.; De Pauw, M.; Van Oene, J. C.; Meuwissen, S. G. M.; Felt-Bersma, R. J. F. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment. Pharmacol. Ther. 2002, 16, 759-767.
22. Movetis files RESOLOR with EMEA for the indication of chronic constipation. Movetis Press Release, 29 May 2008.
23. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment. Pharmacol. Ther. 2001, 15, 1745-1751.
24. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol. Ther. 2001, 15, 1655-1666.
25. 4 receptor partial agonist with promotile activity. Appel-Dingemanse, S. Clin. Pharmacokinet. 2002, 41, 1021-1042.
26. Zelnorm prescribing information.
27. 2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol. 2004, 143, 549-560.
28. Public Health Advisory, March 30, 2007; U.S. Food and Drug Administration: Silver Spring, MD, 2007.
29. Mammen, M.; Choi, S.-K.; Whitesides, G. M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed. 1998, 37, 2754-2794.
30. Wright, D.; Usher, L. Multivalent binding in the design of bioactive compounds. Curr. Org. Chem. 2001, 5, 1107-1131.
31. Kato, S.; Morie, T.; Hino, K.; Kon, T.; Naruto, S.; Yoshida, N.; Karasawa, T.; Matsumoto, J. Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides. J. Med. Chem. 1990, 33, 1406-1413.
32. 4 Receptor Agonists. Chem. Pharm. Bull. 2000, 48, 2003-2008.
33. 4 Receptor Antagonists: Indazole and Benzimidazolone Derivatives. J. Med. Chem. 1998, 41, 1943-1955.
34. 4 receptor agonists and gastric motility stimulants. J. Med. Chem. 1993, 36, 683-689.
35. 4 receptor antagonists: structure-affinity relationships and ligand-receptor interactions. Curr. Top. Med. Chem. 2002, 2, 625-641.
36. 4 binding sites. J. Comput.-Aided Mol. Des. 1997, 11, 589-599.
37. 4 receptor binding site: exploration of a hydrophobic pocket. Br. J. Pharmacol. 2004, 143, 361-370.
38. 4 receptor guided by site-directed mutagenesis and the crystal structure of rhodopsin. J. Comput.-Aided Mol. Des. 2001, 15, 1025-1033.
39. 4 receptor agonists and antagonists. J. Med. Chem. 2006, 49, 1125-1139.
40. 4 receptor agonists. Eur. J. Med. Chem. 1999, 34, 977-989.
41. Harada, H.; Yamazaki, H.; Toyotomi, Y.; Tateishi, H.; Mine, Y.; Yoshida, N.; Kato, S. Novel N-[1-(1-substituted 4-piperidinylmethyl)-4-piperidinyl] benzamides as potent colonic prokinetic agents. Bioorg. Med. Chem. Lett. 2002, 12, 967-970.
42. 4) receptor. Eur. J. Med. Chem. 1999, 34, 1101-1108.
43. 3 receptor antagonist for irritable bowel syndrome with diarrhea predominance. Therapy 2005, 2, 559-567.
44. Briejer, M. R.; Bosmans, J. P.; Van Daele, P.; Jurzak, M.; Heylen, L.; Leysen, J. E.; Prins, N. H.; Schuurkes, J. A. J. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur. J. Pharmacol. 2001, 423, 71-83.
45. 4 receptor mediated contractions. Br. J. Pharmacol. 1993, 110, 1593-1599.
46. Adelson, D. W.; Million, M Tracking the moveable feast: sonomicrometry and gastrointestinal motility. News Physiol. Sci. 2004, 19, 27-32.
47. 4 receptor agonist with high intrinsic activity. Naunyn Schmiedeberg's Arch. Pharmacol. 2008, 378, 139-147